Special Reports
Emerging Drug Developer: Follica
Follica starts with a market in search of a therapy Most biotech companies start with an interesting discovery technology or a drug development program and then go out in search of money to fund
Read more...Emerging Drug Developer: Portola Pharmaceuticals
Cash-hungry Portola aims at a blockbuster market Portola Pharmaceuticals isn't cheap to operate. When the South San Francisco-based developer announced it had completed raising $60 million in July,
Read more...Emerging Drug Developer: Tetraphase
Tetraphase readies its move into the clinic Tetraphase Pharmaceuticals' roots go back to Andrew Myers' laboratory at Harvard, where the chemist--who chairs the department of chemistry and chemical
Read more...Emerging Drug Developer: Cytochroma
Cytochroma plans to grow as it advances vitamin D work The business case for Cytochroma is built around the shortcomings of two lead therapies for hyperparathyroidism in patients with chronic kidney
Read more...Emerging Drug Developer: Synosia Therapeutics
Synosia relies on relationships to grow fast Back in 2005, Synosia Therapeutics was little more than a gleam in a venture capitalist's eye. Bradley Bolzon, an experienced biotech player and an
Read more...2008's Billion-dollar deals (H1)
The first half of 2008 has drawn to a close, with deal-making still on a roll. In the first six months of this year, companies inked six pacts--both buyouts and licensing deals--that exceed the
Read more...Emerging Drug Developer: VLST
VLST readies itself for a shift into the clinic Some biotechs thrive best outside the glare of public attention. And VLST, a fledgling graduate of Seattle's Accelerator Corp., has been using its
Read more...Emerging Drug Developer: CoLucid
CoLucid helps define lean and mean in biotech A roster of new biotech companies has sprung up recently that relies on a virtual business model to keep costs down as they advance therapies to proof of
Read more...The next generation of biotech blockbusters
The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, these biologics could
Read more...Gemin X Pharmaceuticals
Pharma development chief takes on role of biotech entrepreneur Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. There were
Read more...An early look at FDA trends
By Maureen Martino and Tracy Staton It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a
Read more...Top 17 Paychecks in Big Pharma
by Tracy Staton and Maureen Martino Few statistics are as hotly debated as CEO pay reports. Investors, analysts, and the just plain curious all want to know how much the head honcho makes--and how
Read more...Worst Pharma Stocks of 2007
When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to
Read more...Best Pharma Stocks of 2007
When it comes to picking stocks, prediction may be murky, but hindsight is crystal clear. We looked at every company in the Wall Street Journal's pharma sector (plus a few others of our own
Read more...FiercePharma's 2007 trends & 2008 predictions
Take a look at FiercePharma's 2007 year-end round-up and our predictions for the year ahead. 2007 pharma industry trends: 1.
Read more...FiercePharma's Top 10 Articles of 2007
Since FiercePharma was launched in August we’ve published hundreds of articles, but there are some that are clear favorites with our readers. Check out this list of our most-read articles in 2007
Read more...SPOTLIGHT: Top 10 drug warnings and recalls of 2007
2007 was a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs--ranked by 2006 sales--that drew new, FDA-issued warnings or withdrawals.
Read more...Top 10 Drug Warnings and Recalls of 2007
2007 has been a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs with new, FDA-issued warnings or withdrawals this year. The drugs are ranked by
Read more...GSK plant closure begins 5,000 job cuts
Count GlaxoSmithKline's Puerto Rican plant as an early Avandia casualty. The drug maker will close the factory in Cidra, Puerto Rico, and transfer production of the diabetes med (and its cousin
Read more...Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

